Relaxin-2 Does Not Ameliorate Nephropathy in an Experimental Model of Type-1 Diabetes

Relaxin-2 Does Not Ameliorate Nephropathy in an Experimental Model of Type-1 Diabetes

Background/Aims: In diabetic nephropathy (DN), the current angiotensin-II-blocking pharmacotherapy is frequently failing. For diabetic cardiomyopathy (DC), there is no specific remedy available. Relaxin-2 (Rlx) - an anti-fibrotic, anti-inflammatory, and vasoprotecting peptide - is a candidate drug f...

Full description

Bibliographic Details
Main Authors: Thomas Bernd Dschietzig, Katharina Krause-Relle, Maud Hennequin, Karoline von Websky, Jan Rahnenführer, Jana Ruppert, Hans Jürgen Grön, Franz Paul Armbruster, Ross A. D. Bathgate, Joerg R. Aschenbach, Wolf-Georg Forssmann, Berthold Hocher
Format: Article
Language:English
Published: Karger Publishers 2015-03-01
Series:Kidney & Blood Pressure Research
Subjects:
Diabetic nephropathy
Diabetic cardiomyopathy
Fibrosis
Inflammation
Relaxin
Online Access:http://www.karger.com/Article/FullText/368484

Similar Items

Similar Items